Assessment of adalimumab self injection in Crohn's disease-Pearl survey

Assessment of adalimumab self injection in Crohn's disease-Pearl survey - Assessment of adalimumab self injection

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000007197

Enrollment

100

Registered

2012-02-01

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Crohn's disease patients who under treatment of adalimumab self injection

Exclusion criteria

Exclusion criteria: Patients who do not give consent to participate in the survey.

Design outcomes

Primary

Measure	Time frame
Satisfaction rate of adalimumab self injection.	—

Secondary

Measure	Time frame
Pain of adalimumab self injection. Adherence of adalimumab self injection. Anxiety of adalimumab self injection. Problems of adalimumab self injection. etc	—

Countries

Japan

Contacts

Public ContactFumihito Hirai

Fukuoka University Chikushi Hospital Department of Gastroenterology

fuhirai@cis.fukuoka-u.ac.jp

Outcome results